diflomotecan has been researched along with Neutropenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buil-Bruna, N; Garrido, MJ; Mangas-Sanjuan, V; Soto, E; Trocóniz, IF | 1 |
| Beijnen, JH; Cendrós, JM; Friberg, LE; Huitema, AD; Karlsson, MO; Keizer, RJ; Obach, R; Peraire, C; Schellens, JH; Soto, E; Trocóniz, IF; Wanders, J | 1 |
| Cendrós, JM; Garrido, MJ; Obach, R; Peraire, C; Principe, P; Segura, C; Trocòniz, IF | 1 |
2 trial(s) available for diflomotecan and Neutropenia
| Article | Year |
|---|---|
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Discovery; Female; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Predictive Value of Tests; Sulfonamides; Treatment Outcome | 2011 |
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; France; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Neutropenia | 2006 |
1 other study(ies) available for diflomotecan and Neutropenia
| Article | Year |
|---|---|
Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
Topics: Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Cell Proliferation; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Stem Cells | 2015 |